Copyright
©2014 Baishideng Publishing Group Inc.
World J Methodol. Jun 26, 2014; 4(2): 123-132
Published online Jun 26, 2014. doi: 10.5662/wjm.v4.i2.123
Published online Jun 26, 2014. doi: 10.5662/wjm.v4.i2.123
Table 7 Disease-control/response related events used to define secondary end points in randomized trials of metastatic castration-resistant prostate cancer
| Progression event | Trial number | Ref. |
| Clinical | 1 | [27] |
| Pain | 5 | [7-9,18,21] |
| Radiological | 11 | [4,5,7,19,20,21,24,26,28,37,38] |
| Prostate-specific antigen | 19 | [4,5,7,8,19-22,24,25,27-29,33,35, 37,38,40,41] |
| Alkaline phosphatase | 1 | [10] |
| Immunity | 1 | [32] |
- Citation: Colloca G, Venturino A, Governato I. End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review. World J Methodol 2014; 4(2): 123-132
- URL: https://www.wjgnet.com/2222-0682/full/v4/i2/123.htm
- DOI: https://dx.doi.org/10.5662/wjm.v4.i2.123